{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T09:09:41Z","timestamp":1778490581278,"version":"3.51.4"},"reference-count":46,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This study assessed the gastrointestinal (GI) safety profiles of tigecycline, omadacycline, and eravacycline through a retrospective disproportionality analysis of reports submitted to the FDA Adverse Event Reporting System (FAERS) between the second quarter of 2005 and the first quarter of 2024. Among 3,261 adverse event reports associated with these agents, 809 (24.8 %) involved gastrointestinal disorders, with tigecycline accounting for the largest proportion (588 reports), followed by omadacycline (197) and eravacycline (24). Disproportionality analysis revealed that gastrointestinal disorders ranked among the top three system organ classes for all three drugs, with positive signals observed for tigecycline (ROR = 1.63), omadacycline (ROR = 3.04), and eravacycline (ROR = 1.79), the strongest association being with omadacycline. While most GI events were consistent with known safety information, several unexpected signals were identified, including gastrointestinal haemorrhage, melena, small-intestinal obstruction, tongue discolouration, and intestinal perforation for tigecycline, as well as lip swelling and tongue discolouration for omadacycline. The median onset times of GI events were 4, 0, and 2.5 days for tigecycline, omadacycline, and eravacycline, respectively, with nearly half of the events occurring within three days of treatment initiation. These findings reveal distinct GI safety patterns among newer tetracycline-derived antibiotics and underscore the importance of early and route-specific monitoring in clinical practice.<\/jats:p>","DOI":"10.2478\/acph-2026-0001","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T10:00:36Z","timestamp":1766138436000},"page":"1-20","source":"Crossref","is-referenced-by-count":0,"title":["Gastrointestinal risk profile of tigecycline, omadacycline and eravacycline: Evidence from the FDA adverse event reporting system"],"prefix":"10.2478","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4401-0281","authenticated-orcid":false,"given":"Zhu","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pediatrics, The First College of Clinical Medical Science China Three Gorges University & Yichang Central People\u2019s Hospital Yichang , Hubei , P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0845-9445","authenticated-orcid":false,"given":"Guoping","family":"Gan","sequence":"additional","affiliation":[{"name":"College of Pharmacy , Hubei University of Chinese Medicine Wuhan , Hubei , P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5085-8819","authenticated-orcid":false,"given":"Haiping","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First College of Clinical Medical Science China Three Gorges University & Yichang Central People\u2019s Hospital Yichang , Hubei , P. R. China"},{"name":"College of Pharmacy , Hubei University of Chinese Medicine Wuhan , Hubei , P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"2026051108174709200_j_acph-2026-0001_ref_001","doi-asserted-by":"crossref","unstructured":"T. H. Grossman, Tetracycline antibiotics and resistance, Cold Spring Harbor Perspect. Med. 6(4) (2016) Article ID a025387 (24 pages); https:\/\/doi.org\/10.1101\/cshperspect.a025387","DOI":"10.1101\/cshperspect.a025387"},{"key":"2026051108174709200_j_acph-2026-0001_ref_002","doi-asserted-by":"crossref","unstructured":"K. L. LaPlante, A. Dhand, K. Wright and M. Lauterio, Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance, Ann. Med. 54(1) (2022) 1686\u20131700; https:\/\/doi.org\/10.1080\/07853890.2022.2085881","DOI":"10.1080\/07853890.2022.2085881"},{"key":"2026051108174709200_j_acph-2026-0001_ref_003","doi-asserted-by":"crossref","unstructured":"H. G. Colaco, A. Barros, A. Neves-Costa, E. Seixas, D. Pedroso, T. Velho, K. L. Willmann, P. Faisca, G. Grabmann, H. S. Yi, M. Shong, V. Benes, S. Weis, T. Kocher and L. F. Moita, Tetracycline antibiotics induce host-dependent disease tolerance to infection, Immunity 54(1) (2021) 53\u201367; https:\/\/doi.org\/10.1016\/j.immuni.2020.09.011","DOI":"10.1016\/j.immuni.2020.09.011"},{"key":"2026051108174709200_j_acph-2026-0001_ref_004","doi-asserted-by":"crossref","unstructured":"G. G. Zhanel, J. Esquivel, S. Zelenitsky, C. K. Lawrence, H. J. Adam, A. Golden, R. Hink, L. Berry, F. Schweizer, M. A. Zhanel, D. Bay, P. R. S. Lagace-Wiens, A. J. Walkty, J. P. Lynch, 3rd and J. A. Karlowsky, Omadacycline: A novel oral and intravenous aminomethylcycline antibiotic agent, Drugs 80(3) (2020) 285\u2013313; https:\/\/doi.org\/10.1007\/s40265-020-01257-4","DOI":"10.1007\/s40265-020-01257-4"},{"key":"2026051108174709200_j_acph-2026-0001_ref_005","doi-asserted-by":"crossref","unstructured":"P. Y. Huang, C. K. Hsu, H. J. Tang and C. C. Lai, Eravacycline: A comprehensive review of in vitro activity, clinical efficacy, and real-world applications, Expert Rev. Anti Infect. Ther. 22(6) (2024) 387\u2013398; https:\/\/doi.org\/10.1080\/14787210.2024.2351552","DOI":"10.1080\/14787210.2024.2351552"},{"key":"2026051108174709200_j_acph-2026-0001_ref_006","doi-asserted-by":"crossref","unstructured":"S. Yaghoubi, A. O. Zekiy, M. Krutova, M. Gholami, E. Kouhsari, M. Sholeh, Z. Ghafouri and F. Maleki, Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: Narrative review, Eur. J. Clin. Microbiol. Infect. Dis. 41(7) (2021) 1003\u20131022; https:\/\/doi.org\/10.1007\/s10096-020-04121-1","DOI":"10.1007\/s10096-020-04121-1"},{"key":"2026051108174709200_j_acph-2026-0001_ref_007","unstructured":"Tigecycline FDA Label, revised 4\/2025; https:\/\/nctr-crs.fda.gov\/fdalabel\/services\/spl\/set-ids\/dd58e0c3-d8a8-4cf2-96f8-9dd08f309579\/spl-doc?hl=tigecycline; last access date July 31, 2025"},{"key":"2026051108174709200_j_acph-2026-0001_ref_008","unstructured":"Omadacycline FDA Label, revised 3\/2025; https:\/\/nctr-crs.fda.gov\/fdalabel\/services\/spl\/setids\/51591524-4703-44c6-8bde-dce3e6a463d1\/spl-doc?hl=omadacycline; last access date July 31, 2025."},{"key":"2026051108174709200_j_acph-2026-0001_ref_009","unstructured":"Eravacycline FDA Label, revised 3\/2025; https:\/\/nctr-crs.fda.gov\/fdalabel\/services\/spl\/set-ids\/a4b188d4-f467-470c-ad7b-25ffbdd8862a\/spl-doc?hl=eravacycline; last access date July 31, 2025."},{"key":"2026051108174709200_j_acph-2026-0001_ref_010","doi-asserted-by":"crossref","unstructured":"Q. Kaewpoowat and L. Ostrosky-Zeichner, Tigecycline: A critical safety review, Expert Opin. Drug Saf. 14(2) (2015) 335\u2013342; https:\/\/doi.org\/10.1517\/14740338.2015.997206","DOI":"10.1517\/14740338.2015.997206"},{"key":"2026051108174709200_j_acph-2026-0001_ref_011","doi-asserted-by":"crossref","unstructured":"F. Lin, R. He, B. Yu, B. Deng, B. Ling and M. Yuan, Omadacycline for treatment of acute bacterial infections: A meta-analysis of phase II\/III trials, BMC Infect. Dis. 23(1) (2023) Article ID 232 (10 pages); https:\/\/doi.org\/10.1186\/s12879-023-08212-0","DOI":"10.1186\/s12879-023-08212-0"},{"key":"2026051108174709200_j_acph-2026-0001_ref_012","doi-asserted-by":"crossref","unstructured":"R. Meng, X. Guan, L. Sun, Z. Fei, Y. Li, M. Luo, A. Ma and H. Li, The efficacy and safety of eravacycline compared with current clinically common antibiotics in the treatment of adults with complicated intra-abdominal infections: A Bayesian network meta-analysis, Front. Med. (Lausanne) 9 (2022) Article ID 935343 (15 pages); https:\/\/doi.org\/10.3389\/fmed.2022.935343","DOI":"10.3389\/fmed.2022.935343"},{"key":"2026051108174709200_j_acph-2026-0001_ref_013","doi-asserted-by":"crossref","unstructured":"K. Eljaaly, J. K. Ortwine, M. Shaikhomer, T. A. Almangour and M. Bassetti, Efficacy and safety of eravacycline: A meta-analysis, J. Glob. Antimicrob. Resist. 24 (2021) 424\u2013428; https:\/\/doi.org\/10.1016\/j.jgar.2021.02.009","DOI":"10.1016\/j.jgar.2021.02.009"},{"key":"2026051108174709200_j_acph-2026-0001_ref_014","doi-asserted-by":"crossref","unstructured":"S. H. Lan, S. P. Chang, C. C. Lai, L. C. Lu and C. M. Chao, The efficacy and safety of omadacycline in treatment of acute bacterial infection: A systemic review and meta-analysis of randomized controlled trials, Medicine (Baltimore) 98(51) (2019) e18426 (6 pages); https:\/\/doi.org\/10.1097\/MD.0000000000018426","DOI":"10.1097\/MD.0000000000018426"},{"key":"2026051108174709200_j_acph-2026-0001_ref_015","doi-asserted-by":"crossref","unstructured":"P. In\u00e1cio, A. Cavaco and M. Airaksinen, The value of patient reporting to the pharmacovigilance system: A systematic review, Br. J. Clin. Pharmacol. 83(2) (2017) 227\u2013246; https:\/\/doi.org\/10.1111\/bcp.13098","DOI":"10.1111\/bcp.13098"},{"key":"2026051108174709200_j_acph-2026-0001_ref_016","doi-asserted-by":"crossref","unstructured":"T. Sakaeda, A. Tamon, K. Kadoyama and Y. Okuno, Data mining of the public version of the FDA Adverse Event Reporting System, Int. J. Med. Sci. 10(7) (2013) 796\u2013803; https:\/\/doi.org\/10.7150\/ijms.6048","DOI":"10.7150\/ijms.6048"},{"key":"2026051108174709200_j_acph-2026-0001_ref_017","doi-asserted-by":"crossref","unstructured":"E. G. Brown, L. Wood and S. Wood, The medical dictionary for regulatory activities (MedDRA), Drug Saf. 20(2) (1999) 109\u2013117; https:\/\/doi.org\/10.2165\/00002018-199920020-00002","DOI":"10.2165\/00002018-199920020-00002"},{"key":"2026051108174709200_j_acph-2026-0001_ref_018","doi-asserted-by":"crossref","unstructured":"E. P. van Puijenbroek, A. Bate, H. G. Leufkens, M. Lindquist, R. Orre and A. C. Egberts, A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions, Pharmacoepidemiol. Drug Saf. 11(1) (2002) 3\u201310; https:\/\/doi.org\/10.1002\/pds.668","DOI":"10.1002\/pds.668"},{"key":"2026051108174709200_j_acph-2026-0001_ref_019","doi-asserted-by":"crossref","unstructured":"C. Khouri, T. Nguyen, B. Revol, M. Lepelley, A. Pariente, M. Roustit and J. L. Cracowski, Leveraging the variability of pharmacovigilance disproportionality analyses to improve signal detection performances, Front. Pharmacol. 12(1) (2021) Article ID 668765 (7 pages); https:\/\/doi.org\/10.3389\/fphar.2021.668765","DOI":"10.3389\/fphar.2021.668765"},{"key":"2026051108174709200_j_acph-2026-0001_ref_020","doi-asserted-by":"crossref","unstructured":"K. J. Rothman, S. Lanes and S. T. Sacks, The reporting odds ratio and its advantages over the proportional reporting ratio, Pharmacoepidemiol. Drug Saf. 13(8) (2004) 519\u2013523; https:\/\/doi.org\/10.1002\/pds.1001","DOI":"10.1002\/pds.1001"},{"key":"2026051108174709200_j_acph-2026-0001_ref_021","doi-asserted-by":"crossref","unstructured":"A. Kumar, The newly available FAERS public dashboard: Implications for health care professionals, Hosp. Pharm. 54(2) (2019) 75\u201377; https:\/\/doi.org\/10.1177\/0018578718795271","DOI":"10.1177\/0018578718795271"},{"key":"2026051108174709200_j_acph-2026-0001_ref_022","doi-asserted-by":"crossref","unstructured":"L. Wang, D. Liu, Y. Lv, L. Cui, Y. Li, T. Li, H. Song, Y. Hao, J. Shen, Y. Wang and T. R. Walsh, Novel plasmid-mediated tet(X5) gene conferring resistance to tigecycline, eravacycline, and omadacycline in a clinical Acinetobacter baumannii isolate, Antimicrob. Agents Chemother. 64(1) (2019) Article ID 10.1128\/AAC.01326-19 (5 pages); https:\/\/doi.org\/10.1128\/AAC.01326-19","DOI":"10.1128\/AAC.01326-19"},{"key":"#cr-split#-2026051108174709200_j_acph-2026-0001_ref_023.1","doi-asserted-by":"crossref","unstructured":"A. J. Kunz Coyne, S. Alosaimy, K. Lucas, A. M. Lagnf, T. Morrisette, K. C. Molina, A. DeKerlegand, M. R. Schrack, S. L. Kang-Birken, A. L. V. Hobbs, J. Agee, N. B. Perkins, M. Biagi, M. Pierce, J. Truong, J. Andrade, J. Bouchard, T. Gore, M. A. King, B. M. Pullinger, K. C. Claeys, S. Herbin, R. Cosimi, S. Tart, M. P. Veve, B. M. Jones, L. M. Rojas, A. K. Feehan, M. R. Scipione, J. J. Zhao, P. Witucki, M. J. Rybak and A. Babiker, Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022, Microbiol. Spectr. 12(1) (2024) e0235123 (14 pages)","DOI":"10.1128\/spectrum.02351-23"},{"key":"#cr-split#-2026051108174709200_j_acph-2026-0001_ref_023.2","doi-asserted-by":"crossref","unstructured":"A. J. Kunz Coyne, S. Alosaimy, K. Lucas, A. M. Lagnf, T. Morrisette, K. C. Molina, A. DeKerlegand, M. R. Schrack, S. L. Kang-Birken, A. L. V. Hobbs, J. Agee, N. B. Perkins, M. Biagi, M. Pierce, J. Truong, J. Andrade, J. Bouchard, T. Gore, M. A. King, B. M. Pullinger, K. C. Claeys, S. Herbin, R. Cosimi, S. Tart, M. P. Veve, B. M. Jones, L. M. Rojas, A. K. Feehan, M. R. Scipione, J. J. Zhao, P. Witucki, M. J. Rybak and A. Babiker, Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022, Microbiol. Spectr. 12","DOI":"10.1128\/spectrum.02351-23"},{"key":"#cr-split#-2026051108174709200_j_acph-2026-0001_ref_023.3","doi-asserted-by":"crossref","unstructured":"(1) (2024) e0235123 (14 pages); https:\/\/doi.org\/10.1128\/spectrum.02351-23","DOI":"10.1128\/spectrum.02351-23"},{"key":"2026051108174709200_j_acph-2026-0001_ref_024","doi-asserted-by":"crossref","unstructured":"J. Rello, Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline, J. Chemother. 17(Suppl. 1) (2005) 12\u201322; https:\/\/doi.org\/10.1179\/joc.2005.17.Supplement-1.12","DOI":"10.1179\/joc.2005.17.Supplement-1.12"},{"key":"2026051108174709200_j_acph-2026-0001_ref_025","doi-asserted-by":"crossref","unstructured":"L. A. Bundrant, E. Tzanis, L. Garrity-Ryan, S. Bai, S. Chitra, A. Manley and S. Villano, Safety and pharmacokinetics of the aminomethylcycline antibiotic omadacycline administered to healthy subjects in oral multiple-dose regimens, Antimicrob. Agents Chemother. 62(2) (2018) Article ID 10.1128\/AAC.01487-17 (9 pages); https:\/\/doi.org\/10.1128\/AAC.01487-17","DOI":"10.1128\/AAC.01487-17"},{"key":"2026051108174709200_j_acph-2026-0001_ref_026","doi-asserted-by":"crossref","unstructured":"J. Ren, Y. Zheng, H. Du, S. Wang, L. Liu, W. Duan, Z. Zhang, L. Heng and Q. Yang, Antibiotic- induced black hairy tongue: Two case reports and a review of the literature, J. Int. Med. Res. 48(10) (2020) Article ID 300060520961279 (11 pages); https:\/\/doi.org\/10.1177\/0300060520961279","DOI":"10.1177\/0300060520961279"},{"key":"2026051108174709200_j_acph-2026-0001_ref_027","doi-asserted-by":"crossref","unstructured":"N. Shaheen and D. F. Ransohoff, Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: Scientific review, JAMA 287(15) (2002) 1972\u20131981; https:\/\/doi.org\/10.1001\/jama.287.15.1972","DOI":"10.1001\/jama.287.15.1972"},{"key":"2026051108174709200_j_acph-2026-0001_ref_028","doi-asserted-by":"crossref","unstructured":"J. S. Overcash, P. Bhiwandi, L. Garrity-Ryan, J. Steenbergen, S. Bai, S. Chitra, A. Manley and E. Tzanis, Pharmacokinetics, safety, and clinical outcomes of omadacycline in women with cystitis: Results from a phase 1b study, Antimicrob. Agents Chemother. 63(5) (2019) Article ID 10.1128\/AAC.02083-18 (10 pages); https:\/\/doi.org\/10.1128\/AAC.02083-18","DOI":"10.1128\/AAC.02083-18"},{"key":"2026051108174709200_j_acph-2026-0001_ref_029","doi-asserted-by":"crossref","unstructured":"H. Arafat, D. Sadaqa and A. Sabateen, Tigecycline-induced pancreatitis in a patient with recurrent malignancy: A case report and literature review, Ann. Med. Surg. (London) 86(6) (2024) 3717\u20133720; https:\/\/doi.org\/10.1097\/MS9.0000000000002077","DOI":"10.1097\/MS9.0000000000002077"},{"key":"2026051108174709200_j_acph-2026-0001_ref_030","doi-asserted-by":"crossref","unstructured":"B. S. Maringanti, V. M. Ganipisetti, S. S. Jun and M. I. Flores, Tigecycline tango: a case of antibiotic-induced pancreatitis, Cureus 15(9) (2023) e44538 (3 pages); https:\/\/doi.org\/10.7759\/cureus.44538","DOI":"10.7759\/cureus.44538"},{"key":"2026051108174709200_j_acph-2026-0001_ref_031","doi-asserted-by":"crossref","unstructured":"S. Opal, T. M. File, T. van der Poll, E. Tzanis, S. Chitra and P. C. McGovern, An integrated safety summary of omadacycline, a novel aminomethylcycline antibiotic, Clin. Infect. Dis. 69(Suppl. 1) (2019) S40\u2013S47; https:\/\/doi.org\/10.1093\/cid\/ciz398","DOI":"10.1093\/cid\/ciz398"},{"key":"2026051108174709200_j_acph-2026-0001_ref_032","doi-asserted-by":"crossref","unstructured":"C. M. Mingora, W. Bullington, P. E. Faasuamalie, A. Levin, G. Porter, R. Stadnick, C. D. Varley, D. Addrizzo-Harris, C. L. Daley, K. N. Olivier, K. L. Winthrop, S. E. Dorman and P. A. Flume, Long-term safety and tolerability of omadacycline for the treatment of mycobacterium abscessus infections, Open Forum Infect. Dis. 10(7) (2023) Article ID ofad335 (6 pages); https:\/\/doi.org\/10.1093\/ofid\/ofad335","DOI":"10.1093\/ofid\/ofad335"},{"key":"2026051108174709200_j_acph-2026-0001_ref_033","doi-asserted-by":"crossref","unstructured":"P. C. McGovern, M. Wible, J. M. Korth-Bradley and A. Quintana, Pancreatitis in tigecycline Phase 3 and 4 clinical studies, J. Antimicrob. Chemother. 69(3) (2014) 773\u2013778; https:\/\/doi.org\/10.1093\/jac\/dkt427","DOI":"10.1093\/jac\/dkt427"},{"key":"2026051108174709200_j_acph-2026-0001_ref_034","doi-asserted-by":"crossref","unstructured":"N. Cui, H. Cai, Z. Li, Y. Lu, G. Wang and A. Lu, Tigecycline-induced coagulopathy: A literature review, Int. J. Clin. Pharm. 41(6) (2019) 1408\u20131413; https:\/\/doi.org\/10.1007\/s11096-019-00912-5","DOI":"10.1007\/s11096-019-00912-5"},{"key":"2026051108174709200_j_acph-2026-0001_ref_035","doi-asserted-by":"crossref","unstructured":"H. Pieringer, B. Schmekal, G. Biesenbach and E. Pohanka, Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline, Ann. Hematol. 89(10) (2010) 1063\u20131064; https:\/\/doi.org\/10.1007\/s00277-010-0911-7","DOI":"10.1007\/s00277-010-0911-7"},{"key":"2026051108174709200_j_acph-2026-0001_ref_036","doi-asserted-by":"crossref","unstructured":"Q. Fan, W. Huang, Y. Weng, X. Xie and Z. Shi, Hypofibrinogenemia induced by high-dose tigecycline-case report and review of literature, Medicine (Baltimore) 99(43) (2020) e22638 (5 pages); https:\/\/doi.org\/10.1097\/MD.0000000000022638","DOI":"10.1097\/MD.0000000000022638"},{"key":"2026051108174709200_j_acph-2026-0001_ref_037","doi-asserted-by":"crossref","unstructured":"H. Duan, L. Yu, F. Tian, Q. Zhai, L. Fan and W. Chen, Antibiotic-induced gut dysbiosis and barrier disruption and the potential protective strategies, Crit. Rev. Food Sci. Nutr. 62(6) (2022) 1427\u20131452; https:\/\/doi.org\/10.1080\/10408398.2020.1843396","DOI":"10.1080\/10408398.2020.1843396"},{"key":"2026051108174709200_j_acph-2026-0001_ref_038","doi-asserted-by":"crossref","unstructured":"B. E. Dawes, J. Gao, C. Atkins, J. T. Nelson, K. Johnson, P. Wu and A. N. Freiberg, Human neural stem cell-derived neuron\/astrocyte co-cultures respond to La Crosse virus infection with proinflammatory cytokines and chemokines, J. Neuroinflammation 15(1) (2018) Article ID 315 (15 pages); https:\/\/doi.org\/10.1186\/s12974-018-1356-5","DOI":"10.1186\/s12974-018-1356-5"},{"key":"2026051108174709200_j_acph-2026-0001_ref_039","doi-asserted-by":"crossref","unstructured":"S. Andrei, G. Droc and G. Stefan, FDA approved antibacterial drugs: 2018\u20132019, Discoveries (Craiova) 7(4) (2019) e102 (11 pages); https:\/\/doi.org\/10.15190\/d.2019.15","DOI":"10.15190\/d.2019.15"},{"key":"2026051108174709200_j_acph-2026-0001_ref_040","doi-asserted-by":"crossref","unstructured":"L. Vidal, I. Ben Dor, M. Paul, N. Eliakim-Raz, E. Pokroy, K. Soares-Weiser and L. Leibovici, Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients, Cochrane Database Syst. Rev. (10) (2013) Article ID CD003992 (66 pages); https:\/\/doi.org\/10.1002\/14651858.CD003992.pub3","DOI":"10.1002\/14651858.CD003992.pub3"},{"key":"2026051108174709200_j_acph-2026-0001_ref_041","doi-asserted-by":"crossref","unstructured":"H. K. Li, M. Scarborough, R. Zambellas, C. Cooper, I. Rombach, A. S. Walker, B. A. Lipsky, A. Briggs, A. Seaton, B. Atkins, A. Woodhouse, A. Berendt, I. Byren, B. Angus, H. Pandit, D. Stubbs, M. McNally, G. Thwaites and P. Bejon, Oral versus intravenous antibiotic treatment for bone and joint infections (OVIVA): Study protocol for a randomised controlled trial, Trials 16 (2015) Article ID 583 (12 pages); https:\/\/doi.org\/10.1186\/s13063-015-1098-y","DOI":"10.1186\/s13063-015-1098-y"},{"key":"2026051108174709200_j_acph-2026-0001_ref_042","doi-asserted-by":"crossref","unstructured":"S. Villano, J. Steenbergen and E. Loh, Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections, Future Microbiol. 11(1) (2016) 1421\u20131434; https:\/\/doi.org\/10.2217\/fmb-2016-0100","DOI":"10.2217\/fmb-2016-0100"},{"key":"2026051108174709200_j_acph-2026-0001_ref_043","doi-asserted-by":"crossref","unstructured":"S. Lucas, J. Ailani, T. R. Smith, A. Abdrabboh, F. Xue and M. S. Navetta, Pharmacovigilance: Reporting requirements throughout a product\u2019s lifecycle, Ther. Adv. Drug Saf. 13(1) (2022) Article ID 20420986221125006 (16 pages); https:\/\/doi.org\/10.1177\/20420986221125006","DOI":"10.1177\/20420986221125006"},{"key":"2026051108174709200_j_acph-2026-0001_ref_044","doi-asserted-by":"crossref","unstructured":"K. Staller, H. P. Parkman, K. B. Greer, D. A. Leiman, M. J. Zhou, S. Singh, M. Camilleri, O. Altayar (on behalf of the AGA Clinical Guidelines Committee), AGA clinical practice guideline on management of gastroparesis, Gastroenterology 169(5) (2025) 828\u2013861; https:\/\/doi.org\/10.1053\/j.gastro.2025.08.004","DOI":"10.1053\/j.gastro.2025.08.004"}],"container-title":["Acta Pharmaceutica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/acph-2026-0001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T08:24:16Z","timestamp":1778487856000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/acph-2026-0001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,25]]},"published-print":{"date-parts":[[2026,3,1]]}},"alternative-id":["10.2478\/acph-2026-0001"],"URL":"https:\/\/doi.org\/10.2478\/acph-2026-0001","relation":{},"ISSN":["1846-9558"],"issn-type":[{"value":"1846-9558","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}